Patient characteristics
No. . | Age, y/sex . | TNM stage . | Pretreatment therapy . | TBI before treatment . | TBI after treatment . | Clinical response . | DTH . |
|---|---|---|---|---|---|---|---|
| 1 | 47/F | IIb | PUVA | 3.3 | 1 | PR | Lysate− |
| IFN-α | Lysate/DC+++ | ||||||
| RT | KLH+++ | ||||||
| Retinoids | |||||||
| MTX | |||||||
| 2 | 52/F | Ib | PUVA | 3.0 | 1 | PR | Lysate− |
| Retinoids | Lysate/DC++ | ||||||
| IFN-α | KLH+++ | ||||||
| RT | |||||||
| 3 | 64/F | Ib | PUVA | 3.0 | 4.3 | PD | Lysate− |
| Retinoids | Lysate/DC+ | ||||||
| RT | KLH+++ | ||||||
| 4 | 62/M* | IIb | Steroids | 2.3 | 4.3 | PD | Lysate− |
| RT | Lysate/DC+ | ||||||
| KLH++ | |||||||
| 5 | 62/M | Ia | PUVA | 1 | 0 | CR | Lysate+ |
| Steroids | Lysate/DC+ | ||||||
| KLH+++ | |||||||
| 6 | 65/M* | IVa | PUVA | 4.3 | 6.3 | PD | ND |
| RT | |||||||
| IFN-α | |||||||
| Chemotherapy | |||||||
| 7 | 74/M* | IIb | PUVA | 5.3 | 6.3 | PD | ND |
| UVB | |||||||
| RT | |||||||
| 8 | 57/M | Ib | Steroids | 3 | 1 | PR | Lysate+ |
| Lysate/DC++ | |||||||
| KLH+++ | |||||||
| 9 | 47/M | IIb | UVB | 4.3 | 6.3 | PD | Lysate+ |
| RT, IFN-α | Lysate/DC+ | ||||||
| Retinoids | KLH++ | ||||||
| Chemotherapy | |||||||
| PUVA | |||||||
| 10 | 69/F | III | UVB | NA | NA | PR | Lysate− |
| RT | Lysate/DC+ | ||||||
| Photopheresis | KLH++ |
No. . | Age, y/sex . | TNM stage . | Pretreatment therapy . | TBI before treatment . | TBI after treatment . | Clinical response . | DTH . |
|---|---|---|---|---|---|---|---|
| 1 | 47/F | IIb | PUVA | 3.3 | 1 | PR | Lysate− |
| IFN-α | Lysate/DC+++ | ||||||
| RT | KLH+++ | ||||||
| Retinoids | |||||||
| MTX | |||||||
| 2 | 52/F | Ib | PUVA | 3.0 | 1 | PR | Lysate− |
| Retinoids | Lysate/DC++ | ||||||
| IFN-α | KLH+++ | ||||||
| RT | |||||||
| 3 | 64/F | Ib | PUVA | 3.0 | 4.3 | PD | Lysate− |
| Retinoids | Lysate/DC+ | ||||||
| RT | KLH+++ | ||||||
| 4 | 62/M* | IIb | Steroids | 2.3 | 4.3 | PD | Lysate− |
| RT | Lysate/DC+ | ||||||
| KLH++ | |||||||
| 5 | 62/M | Ia | PUVA | 1 | 0 | CR | Lysate+ |
| Steroids | Lysate/DC+ | ||||||
| KLH+++ | |||||||
| 6 | 65/M* | IVa | PUVA | 4.3 | 6.3 | PD | ND |
| RT | |||||||
| IFN-α | |||||||
| Chemotherapy | |||||||
| 7 | 74/M* | IIb | PUVA | 5.3 | 6.3 | PD | ND |
| UVB | |||||||
| RT | |||||||
| 8 | 57/M | Ib | Steroids | 3 | 1 | PR | Lysate+ |
| Lysate/DC++ | |||||||
| KLH+++ | |||||||
| 9 | 47/M | IIb | UVB | 4.3 | 6.3 | PD | Lysate+ |
| RT, IFN-α | Lysate/DC+ | ||||||
| Retinoids | KLH++ | ||||||
| Chemotherapy | |||||||
| PUVA | |||||||
| 10 | 69/F | III | UVB | NA | NA | PR | Lysate− |
| RT | Lysate/DC+ | ||||||
| Photopheresis | KLH++ |
Patient 1 continued subcutaneous IFN-α treatment during vaccination. Patient 8 used an intermediate potency topical steroid once a week. Patient 9 continued to use retinoids and intralesional IFN-α. Partial remission in the stage 3 patient 10 with Sézary syndrome was defined as greater than 50% reduction in erythroderma lasting for more than 1 month. Some additional tumors were treated with radiotherapy or topical imiquimod. Stabilization and regression occurred, even for tumors that received no additional therapy.
RT indicates radiotherapy; MTX, methotrexate; ND, not done; NA, not applicable; PD, progressive disease; −, less than 3 mm; +, 3-10 mm; ++, 11-20 mm; and +++, more than 20 mm.
indicates deceased.